| Name | Title | Contact Details |
|---|
Arch Therapeutics, Inc. is a biotechnology company developing a novel approach to stop bleeding (hemostasis), control leaking (sealant) and manage wounds during surgery, trauma and interventional care. Arch is developing products based on an innovative self-assembling barrier technology platform with the goal of making care faster and safer for patients. Arch has received regulatory authorization to market AC5 Advanced Wound System and AC5 Topical Hemostat as medical devices in the United States and Europe, respectively. Arch`s development stage product candidates include AC5-G, AC5-V and AC5 Surgical Hemostat, among others.1,2
GrayBug® is a platform drug delivery company that is developing proprietary controlled release technologies for ophthalmic pharmaceutical indications. The company`s lead product is a polymer-drug biomolecular conjugate for the treatment of neovascular diseases, including age-related macular degeneration (AMD). GrayBug also has a proprietary platform technology that allows sustained drug delivery into various compartments of the eye while minimizing inflammation common with current controlled release technologies applied to the eye.
SHYFT has been an integral part of the life sciences ecosystem for over 10 years and as the market undergoes a dramatic transformation to deliver more personalized and value-based medicine, the role of SHYFT has never been more important. We built the SHYFT Platform to help life science companies integrate clinical and commercial data and translate it into patient-centric intelligence and analytics for use across functional groups, shortening development cycles and commercialization activities while improving the probability of success. With a long history of success and deep client partnerships, we understand the market transformation and the actionable intelligence required for successful launch, growth and maintenance of new therapies. At SHYFT, we collaborate with our clients to ensure their success not only today, but in the future by providing flexible, agile solutions based on deep industry expertise. With an impressive customer retention rate, we`re committed to our client`s success and serve as a true partner in the transformation.
EYELA Tokyo Rikakikai Co is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Woodside Senior Communities is a Green Bay, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.